For an adult outpatient with iron‑deficiency anemia who is not on dialysis and has no severe cardiac disease, infection, or IV‑iron hypersensitivity, which is preferred for infusion: Injectafer (ferric carboxymaltose) or Venofer (iron sucrose)?

Injectafer (Ferric Carboxymaltose) is Preferred Over Venofer (Iron Sucrose) for Outpatient Infusion

For adult outpatients with iron-deficiency anemia who are not on dialysis, Injectafer (ferric carboxymaltose) is the superior choice because it delivers complete iron repletion in 1-2 visits versus 4-7 visits required for Venofer (iron sucrose), with equivalent efficacy and safety. 1

Why Injectafer Wins: The Practical Advantage

The 2024 expert consensus guidelines explicitly state that formulations enabling total dose infusion (TDI) are optimal for ambulatory patients 1. Here's the critical distinction:

• Injectafer: 750-1000 mg per infusion, typically 1-2 doses total 2
• Venofer: Maximum 200-250 mg per infusion, requiring 4-7 visits for complete repletion 1

The guidelines are unequivocal: "In that every head-to-head comparison of the salts [including iron sucrose] to the four formulations which enable a TDI reported no difference in efficacy or safety, for ambulatory patients receiving IV iron their use is suboptimal." 1

Evidence of Equivalent Efficacy and Safety

The REPAIR-IDA trial directly compared these agents in 2,584 patients with iron-deficiency anemia and chronic kidney disease 3:

• Hemoglobin increase: 1.13 g/dL (Injectafer) vs 0.92 g/dL (Venofer)
• Response rate: 48.6% achieved ≥1.0 g/dL increase with Injectafer vs 41.0% with Venofer
• Safety: No significant difference in major adverse cardiac events (death, MI, stroke)

Practical Administration

Injectafer protocol 1, 2:

• 750-1000 mg diluted in normal saline
• Infused over 15 minutes
• Repeat dose after 7 days if needed (for IDA) or 6 weeks (for heart failure)
• No test dose required

Venofer limitations 1:

• Maximum 200 mg per dose due to higher labile free iron release
• Requires multiple visits (typically 5 doses of 200 mg weekly)
• Unacceptable infusion reactions occur at doses >250 mg

Cost-Effectiveness Despite Higher Acquisition Cost

While Injectafer costs more per dose ($3,470 for typical course vs $441.50 for Venofer) 2, the total cost is offset by:

• Fewer infusion visits (1-2 vs 5)
• Reduced nursing time and facility fees
• Lower risk of treatment abandonment due to visit burden
• Decreased likelihood of extravasation from multiple infusions 1

Multiple analyses confirm Injectafer is cost-effective when accounting for total healthcare utilization 4, 5.

Important Safety Consideration: Hypophosphatemia

The main caveat with Injectafer is transient hypophosphatemia, occurring in approximately 43% of patients 6. This results from induction of fibroblast growth factor 23, causing renal phosphate wasting 7.

Clinical implications:

• Usually asymptomatic and self-limited
• Check phosphate levels before repeat dosing if <3 months since last treatment 8
• Monitor for symptoms: fatigue, muscle weakness, bone pain, fractures (rare) 8
• Higher risk with multiple treatments

This is a mechanistic side effect, not a safety signal requiring treatment avoidance in most patients.

When to Monitor More Closely

Both agents require 30-minute post-infusion observation for hypersensitivity reactions 8. Complement activation-related pseudo-allergy (CARPA) can occur with any IV iron but is rare and manageable by:

• Stopping infusion temporarily
• Restarting at slower rate after 15 minutes
• Avoiding diphenhydramine (side effects mimic worsening reaction) 2

Injectafer may cause transient hypertension with facial flushing 8, 3—monitor blood pressure during and after infusion.

The Bottom Line Algorithm

For non-dialysis outpatients with iron-deficiency anemia:

1. Choose Injectafer as first-line for convenience and completion rates
2. Administer 750-1000 mg IV over 15 minutes
3. Repeat once after 7 days if needed for complete repletion
4. Check phosphate before repeat dosing if <3 months from prior treatment
5. Reserve Venofer only for patients with prior Injectafer intolerance or institutional formulary restrictions

The evidence strongly favors Injectafer for outpatient iron repletion based on patient convenience, treatment completion, and equivalent safety—making it the rational default choice for ambulatory iron-deficiency anemia management.